Platelets in the prediction of XXXX risk.

@entity1 @entity455 @entity583 @entity556 @entity1423 @entity49 @entity1150 @entity613 @entity715 @entity5582
A study is reported which tries to identify those members of the general population who may be at increased risk of @entity455 . It is probable that @entity1 who have had previous @entity715 episodes are inherently more at risk of further episodes and that a @entity715 many months ago will not affect current tests. Accordingly we carried out a number of tests involving platelets on 'controls', and on @entity1 with a past history of either @entity583 or @entity1150 ( @entity1150 ) and @entity1 suffering from @entity613 who also are assumed to be at higher risk than the controls. Differences were demonstrated between controls and @entity1 groups and these differences were utilized to develop statistical functions with the ability to discriminate between the groups. The functions were then tested using a second set of data from similar groups. Those designed to discriminate between @entity583 @entity1 and controls and between @entity1 with @entity613 and controls were validated. The heparin @entity556 clotting time was found to be the prime predictor variable; the platelet count, platelet volume, platelet factor 3 clotting time and the bleeding time have some predictive value. The @entity5582 clotting time, @entity1423 and platelet adhesiveness tests as measured were not found to have discriminating potential. It is suggested that these appropriate risk functions could be of practical value in identifying members of the general population who may be at greater risk than average. The discriminate functions for @entity1150 @entity1 and controls could not be validated, suggesting differences in platelet involvement in arterial and @entity49 .
